Selvigaltin

N/A

Report date: 2026/04/16 20:00:17
NME

Base Information

Drug NameSelvigaltin
Drug Alias NameGB-1211GB1211
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionGalectin-3 inhibitors
TargetsGalectin-3
Therapy Area/IndicationsHepatic InsufficiencyMetabolic Dysfunction-Associated Steatotic Liver DiseaseCarcinoma, Non-Small-Cell Lung +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBulgariaUnited StatesPoland +[7] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesGalecto Inc
China Registration ClassN/A

Develop Information

Active CompaniesGalecto Biotech AB
Inactive CompaniesRoswell Park Cancer Institute
Active IndicationsHepatic InsufficiencyCarcinoma, Non-Small-Cell LungSquamous Cell Carcinoma of Head and Neck +[4] 
Inactive IndicationsMetabolic Dysfunction-Associated Steatotic Liver DiseaseMultiple Myeloma

Other Information

ATC CodeN/A
Related LinksN/A